Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
Public ClinicalTrials.gov record NCT05112536. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients With Early-Stage Triple Negative Breast Cancer (TNBC)
Study identification
- NCT ID
- NCT05112536
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- G1 Therapeutics, Inc.
- Industry
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Interventions
- Trilaciclib Drug
- Cylophosphamide Drug
- Doxorubicin Drug
- Paclitaxel Drug
- Carboplatin (Investigator discretion) Drug
- Pembrolizumab (Investigator discretion) Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2, 2022
- Primary completion
- Oct 30, 2022
- Completion
- Mar 12, 2023
- Last update posted
- Mar 11, 2024
2022 – 2023
United States locations
- U.S. sites
- 7
- U.S. states
- 5
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cancer and Blood Specialty Clinic | Los Alamitos | California | 90720 | — |
| UCLA Department of Medicine - Hematology/Oncology | Santa Monica | California | 90404 | — |
| PIH Health | Whittier | California | 90602 | — |
| Nebraska Hematology-Oncology, P.C. | Lincoln | Nebraska | 68506 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05112536, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05112536 live on ClinicalTrials.gov.